1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Atopic Dermatitis Treatment Market: North America to Remain Dominant Regional Market Through 2027: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027

Atopic Dermatitis Treatment Market: North America to Remain Dominant Regional Market Through 2027: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027

  • June 2017
  • 182 pages
  • ID: 5043393
  • Format: PDF
  • Future Market Insight Global & Consulting Pvt Ltd
Up to $2000 off Until Nov 30th 2020


Table of Contents

The global atopic dermatitis treatment market is poised to grow from close to US$ 7,225 Mn in 2017 to nearly US$ 24,000 Mn by 2027 end. This represents a CAGR of 12.8% over the forecast period. Revenue from the global atopic dermatitis treatment market is estimated to increase 4.1X during the period 2017 – 2027. This massive growth can be attributed to a rising prevalence of atopic dermatitis across the world as well as the introduction of innovative therapeutic options.

Industry consolidations leading to faster time-to-market in North America

Various companies are focussed on partnerships with other companies with products in advanced stages of development to enable quicker approval and marketing of their products. Allergan plc, a leading global pharmaceutical company, successfully completed purchasing all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focussed on innovative development programmes for dermatologic conditions in Oct 2016. The completion of the Vitae acquisition has added highly differentiated development compounds to Allergan’s medical dermatology pipeline. The parent company is able to leverage its clinical development expertise and regulatory knowledge to ensure a win-win situation through this partnership.

New classes of products launched in North America boosting the atopic dermatitis treatment market

Since December 2016, two new classes of drugs were launched targeting both mild-to-moderate atopic dermatitis as well as severe atopic dermatitis. The launch of new classes of drugs gives patients and healthcare professionals alternatives to other classes of drugs such as corticosteroids, which carry the risk of side effects and calcineurin inhibitors, which do not have patent protection anymore and are open to generic alternatives. The U.S. Food and Drug Administration (FDA) approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older in Dec 2016. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) inhibitor.

Side effects and high costs associated with biologic therapy may hamper the market in North America

Dupixent can cause side effects such as serious allergic reactions and eye problems, such as pink eye (conjunctivitis) and inflammation of the cornea (keratitis). The most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching. Additionally, the developers of the biologic therapy Dupixent have priced the drug at approximately US$ 37,000/year. It is uncertain if payers will cover the cost of treatment, considering other lower cost alternatives; which could hinder the adoption of the drug.

Global Atopic Dermatitis Treatment Market Attractiveness Analysis, by Region

North America dominated the global atopic dermatitis treatment market in terms of revenue in 2017, and the trend is projected to continue throughout the forecast period. North America is the most attractive regional market, with an attractiveness index of 3.4 over the forecast period. Revenue from the North America atopic dermatitis treatment market is anticipated to increase at a CAGR of 16.0% over 2017–2027, to reach a market valuation in excess of US$ 10,000 Mn by 2027. Western Europe is the second largest market in terms of revenue growth, anticipated to reach a market valuation of more than US$ 7800 Mn by the end of the forecast period – depicting a CAGR of 14.0%.

Increasing R&D focus on novel biologics will shape future corporate strategies

As the atopic dermatitis treatment market is currently highly generalised and there are only two key patent protected (U.S only) brands, no distinct trends exist. However, over the coming decade, the introduction of biologics, in particular interleukin inhibitors, will emerge as a key future strategy for this marketplace. Historically, Astellas and Novartis were the dominant market players in the atopic dermatitis treatment market for almost a decade, with the launch of the topical calcineurin inhibitor brands Protopic (tacrolimus) and Elidel (pimecrolimus), in the U.S in 2001. Although Astellas continues to maintain its strong standing in the current market, Novartis exited the space in April 2011, with the sale of Elidel’s rights to Meda. To some extent, Novartis continues to have a presence in this market, as some dermatologists opt for its brand edversions of cyclosporine, Sand immune or Neoral, for their atopic dermatitis patients requiring a systemic immune modulator.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Melanoma Drug Market Research Report by Type of Melanoma, by Therapy - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 3949
  • September 2020
  • 144 pages

Melanoma Drug Market Research Report by Type of Melanoma (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma), by Therapy (Chemotherapy, Immunotherapy, ...

  • World
  • Dermatological Condition
  • Cancer
  • Industry analysis

Sanofi $ 3000 October 2020


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on